Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions

Elaine O. Bigelow, Tanguy Y. Seiwert, Carole Fakhry

Research output: Contribution to journalReview articlepeer-review

Abstract

Human papillomavirus (HPV)-related oropharyngeal squamous cell cancer (OPSCC) has emerged as a distinct clinical entity of head and neck cancer with expected high survival. This recognition has led to the investigation of whether a population of patients can be identified who can safely undergo treatment de-escalation, in an effort to minimize long-term treatment toxicity while maintaining excellent survival. The purpose of this review is to describe the rationale for treatment deintensification for HPV-related OPSCC, summarize available results from published clinical trials, explore the methods by which risk groups are assigned, and provide context for the multitude of clinical trials that are currently underway.

Original languageEnglish (US)
Article number104652
JournalOral Oncology
Volume105
DOIs
StatePublished - Jun 2020

Keywords

  • De-escalation
  • Deintensification
  • Human papillomavirus
  • Oropharyngeal squamous cell carcinoma
  • Review
  • Treatment

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions'. Together they form a unique fingerprint.

Cite this